Impact Factor
3.59
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.51
39,442 total citations
h5-index
206
h5 depth signal
Cited share
37.3%
6,070 of 16,284
Total citations
39,442
Citation footprint
Metric signal
2.14
External metric anchor
Self-citation
1.4%
543 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
52,024
China
11,417
United Kingdom
7,020
Canada
6,711
France
5,739
Citing Fields of Research
Oncology
33,212
Immunology
13,896
Breast Cancer
12,706
Lung Cancer
12,250
Liver & Colon Cancer
10,647
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
170,348
Articles tracked across the journal lifetime
Indexed publication set
16,284
6,070 cited publications
Last 12 months
9,942
828.5 publications/month
Open access share
1.0%
103 OA publications in the last year
Leading citing country
United States
52,024 citing publications
Leading citing field
Oncology
33,212 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1983-
v1n1, 1983-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Breast Cancer
Lung Cancer
Immunology
Liver & Colon Cancer
Prostate Cancer
Issuing & Sponsoring Bodies
Contributor
American Society of Clinical Oncology
Broad Categories
Neoplasms
Lung Cancer
Immunology
Liver & Colon Cancer
Urology
Prostate Cancer
Digestive Disorders
Breast Cancer
MeSH Descriptors
Medical Oncology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1200/jco-26-00017
Open DOI
Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer
The ASCOT phase III trial demonstrated that adjuvant S-1, an oral fluoropyrimidine, improved 3-year overall survival (OS) from 67.6% to 77.1% in patients with resected biliary tract cancer (BTC). We report the prespecified final 5-year f...
02
03
DOI 10.1200/jco-25-01967
Open DOI
Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial
PURPOSE: Sleep, fatigue, and pain are common symptoms in cancer survivors. Mindfulness-based cancer recovery (MBCR) and Tai Chi/Qigong (TCQ) are beneficial for these conditions, but have not been studied together. The Mindfulness and Tai...
04
05
06
DOI 10.1200/jco-26-02300
Open DOI
Retraction: Palliative Care Involvement at the End of Life in Advanced Cancer
07
08
DOI 10.1200/jco-26-01847
Open DOI
Bridging the Gap: Precision Oncology for Cancers of Unknown Primary
09
DOI 10.1200/jco-26-00769
Open DOI
Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial
PURPOSE: Circulating tumor DNA (ctDNA) holds promise for prognostication and disease monitoring in solid tumors. However, rare and heterogenous tumors with low mutational burden like soft tissue sarcomas (STS) present a technical challen...
10
DOI 10.1200/jco-26-00469
Open DOI
Purple Blossoms
Purple Blossoms explores the challenge of maintaining the positive attitude of a coach while treating an aggressive disease in an underserved area.
Bibliographical & Catalog Notes
Title from cover.
Supplements accompany some vols.
Annual meetings of the American Society of Clinical Oncology are published as supplement to journal, 2004- .
Also issued online.
Vol. 7, no. 1 (JAN 1989)19911012 Notice not published Printed on acid-free paper